RedHill Biopharma (RDHL) Provides R&D Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St to open higher on oil retreat, tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
RedHill Provides R&D Update
May 22, 2023 7:00 AM EDTRedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatment of COVID-19
RedHill's advanced pipeline also includes: Opaganib in collaboration with the U.S. Government's Radiation and Nuclear Countermeasures Program for development as a potential treatment for Acute Radiation Syndrome (ARS) and... More
